Established in 2020, this company operates two premium supplement brands targeting women seeking a natural alternative to prescription stimulants and the 40+ demographic seeking heart health. With exceptional 71% TTM growth and 60% gross margins, both brands leverage unified marketing, fulfillment, and customer operations for efficient growth. The company will soon implement sustainable flat mailers, representing a retroactive reduction in shipping costs of approximately $700K annually (not in the P&L), providing immediate built-in equity. They maintain premium positioning with elevated packaging, sub-20-minute response times, and clinically validated formulations manufactured in FDA-registered US facilities.

The business delivers exceptional financial performance through predictable subscription revenue, with 55%–60% of sales generating $1.05M combined MRR. Strong customer retention drives an impressive lifetime value (LTV) of $215. The company achieves remarkable cash-flow dynamics through net 120-day supplier terms while collecting payments within 1–3 weeks, creating a powerful negative cash conversion cycle that funds growth without external capital.

Competitive differentiation centers on formulations designed to match clinical-study dosage levels, addressing industry-wide underdosed ingredients. The business demonstrates exceptional scalability and efficiency. Marketing spend has increased from $250K to $650K/mo. while maintaining strong margins, reaching $3.4M SDE and a 12% TTM reduction in ad spend as a percentage of revenue.

The acquisition presents immediate expansion opportunities beyond proven digital channels. Major retail chains, including Walgreens, CVS, and Whole Foods, offer significant growth potential. The proven infrastructure creates a ready platform for additional brands, while international markets remain untapped. The founder is committed to a smooth transition and prefers retaining a meaningful minority stake to support ongoing growth.